Last reviewed · How we verify
Wide-spectrum nutritional supplement
Wide-spectrum nutritional supplement is a Small molecule drug developed by Rossignol Medical Center. It is currently in Phase 2 development. Also known as: NeuroNeeds: Spectrum Needs, NeuroNeeds:Q Needs.
EL219, also known as Turletricin, is a wide-spectrum nutritional supplement being studied in clinical trials for various conditions, including invasive mould infection, refractory childhood epilepsy, impulsive behavior, athletic performance, and Covid-19. The supplement is being compared to standard treatments such as IV antifungal medications like liposomal amphotericin B or voriconazole in some of these trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Wide-spectrum nutritional supplement |
|---|---|
| Also known as | NeuroNeeds: Spectrum Needs, NeuroNeeds:Q Needs |
| Sponsor | Rossignol Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy (NA)
- Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder (PHASE2)
- Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study (PHASE1, PHASE2)
- An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus (NA)
- (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC (NA)
- Clinical Study on Prodovite® VMP35 Supplement on Athletic Performance (NA)
- Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity (NA)
- A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wide-spectrum nutritional supplement CI brief — competitive landscape report
- Wide-spectrum nutritional supplement updates RSS · CI watch RSS
- Rossignol Medical Center portfolio CI
Frequently asked questions about Wide-spectrum nutritional supplement
What is Wide-spectrum nutritional supplement?
Who makes Wide-spectrum nutritional supplement?
Is Wide-spectrum nutritional supplement also known as anything else?
What development phase is Wide-spectrum nutritional supplement in?
Related
- Manufacturer: Rossignol Medical Center — full pipeline
- Also known as: NeuroNeeds: Spectrum Needs, NeuroNeeds:Q Needs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing